Literature DB >> 10535696

Isolation of angiotensin converting enzyme (ACE) binding protein from human serum with an ACE affinity column.

S Thevananther1, A S Brecher.   

Abstract

Immobilized angiotensin-converting enzyme (ACE) was utilized as an affinity ligand to isolate a naturally occurring ACE binding protein from normal human serum. The enzyme was isolated from solubilized bovine lung membrane preparations by lisinopril affinity chromatography. It had an estimated molecular weight of 180 000 and was recognized by the anti-ACE antibody for the rabbit testicular ACE in immunoblots. ACE was immobilized onto epoxy Sepharose as well as Affi-Gel 15. Immobilized ACE on Affi-Gel 15 had higher catalytic activity (0.176 U/mL) compared with the enzyme immobilized on epoxy Sepharose (0.00005 U/mL). Immobilized ACE served as the affinity ligand for the identification of the ACE binding protein in human serum with an estimated molecular weight of 14 000 as observed by SDS polyacrylamide gel electrophoresis. The identification and further characterization of ACE binding proteins in serum and tissues may facilitate the greater understanding of the endogenous regulation of this key enzyme, which is involved in blood pressure homeostasis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10535696

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  7 in total

1.  Conformational changes of blood ACE in chronic uremia.

Authors:  Maxim N Petrov; Valery Y Shilo; Alexandr V Tarasov; David E Schwartz; Joe G N Garcia; Olga A Kost; Sergei M Danilov
Journal:  PLoS One       Date:  2012-11-16       Impact factor: 3.240

2.  ACE phenotyping in human heart.

Authors:  Victoria E Tikhomirova; Olga A Kost; Olga V Kryukova; Elena Z Golukhova; Naida I Bulaeva; Aigerim Z Zholbaeva; Leo A Bokeria; Joe G N Garcia; Sergei M Danilov
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

3.  Lysozyme and bilirubin bind to ACE and regulate its conformation and shedding.

Authors:  Sergei M Danilov; Heinrich Lünsdorf; Henry T Akinbi; Andrew B Nesterovitch; Yuliya Epshtein; Eleftheria Letsiou; Olga V Kryukova; Tobias Piegeler; Elena Z Golukhova; David E Schwartz; Randal O Dull; Richard D Minshall; Olga A Kost; Joe G N Garcia
Journal:  Sci Rep       Date:  2016-10-13       Impact factor: 4.379

4.  A detailed physiologically based model to simulate the pharmacokinetics and hormonal pharmacodynamics of enalapril on the circulating endocrine Renin-Angiotensin-aldosterone system.

Authors:  Karina Claassen; Stefan Willmann; Thomas Eissing; Tobias Preusser; Michael Block
Journal:  Front Physiol       Date:  2013-02-08       Impact factor: 4.566

5.  New perspectives in the renin-angiotensin-aldosterone system (RAAS) II: albumin suppresses angiotensin converting enzyme (ACE) activity in human.

Authors:  Miklós Fagyas; Katalin Úri; Ivetta M Siket; Gábor Á Fülöp; Viktória Csató; Andrea Daragó; Judit Boczán; Emese Bányai; István Elek Szentkirályi; Tamás Miklós Maros; Tamás Szerafin; István Édes; Zoltán Papp; Attila Tóth
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

6.  New perspectives in the renin-angiotensin-aldosterone system (RAAS) III: endogenous inhibition of angiotensin converting enzyme (ACE) provides protection against cardiovascular diseases.

Authors:  Miklós Fagyas; Katalin Úri; Ivetta M Siket; Andrea Daragó; Judit Boczán; Emese Bányai; István Édes; Zoltán Papp; Attila Tóth
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

7.  New perspectives in the renin-angiotensin-aldosterone system (RAAS) I: endogenous angiotensin converting enzyme (ACE) inhibition.

Authors:  Miklós Fagyas; Katalin Úri; Ivetta M Siket; Andrea Daragó; Judit Boczán; Emese Bányai; István Édes; Zoltán Papp; Attila Tóth
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.